Dave S.B. Hoon, Professor and Director of Translational Research at the Saint John’s Cancer Institute (SJCI PHS), interacts with external academic, industry, government agencies, and international cancer centers to develop innovative translational cancer research opportunities.

Dave S.B. Hoon, Professor and Director of Dept. of Translational Molecular Medicine at the John Wayne Cancer Institute, interacts with external academic, industry, government agencies, and international cancer centers to develop innovative translational cancer research opportunities. He has over 30 patents on his studies and has co-authored ...

Hoon Woo‬ - ‪Google Scholar‬. Is God the Author of Sin? Jonathan Edwards's Theodicy. Karl Barth’s Doctrine of the Atonement and Universalism.”

2021年5月8日 · In a recent paper published in Nature, Boix et al. 1 developed an integrated platform on epigenomic maps that represents a significant updated resource in human regulatory circuitry as related to...

Meet the members of the Molecular Medicine and Sequencing Center's team located in Santa Monica, California, and led by Dr. David S.B. Hoon. Translational Research 310-449-5264 Cancer Immunology

The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.

2019年1月1日 · Semantic Scholar profile for Dave S.B. Hoon, with 10 highly influential citations and 12 scientific research papers.

2023年11月6日 · miR-181a is a key factor controlling the STING pathway and driving PARPi and platinum-based drug resistance in TNBC and OvCa. The miR-181a-STING axis can be used as a potential marker for predicting PARPi responses in TNBC and OvCa tumors.

ORCID record for Dave SB Hoon. ORCID provides an identifier for individuals to use with their name as they engage in research, scholarship, and innovation activities.

Dave S.B. Hoon, Professor and Director of Dept. of Translational Molecular Medicine at the John Wayne Cancer Institute, interacts with external academic, industry, government agencies, and international cancer centers to develop innovative translational cancer research opportunities.